HER-2/neu overexpression and amplification in uterine serous papillary carcinoma:: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization

被引：54

作者：

Odicino, F. E. ^{[1
]}

Bignotti, E. ^{[1
]}

Rossi, E. ^{[2
]}

Pasinetti, B. ^{[1
]}

Tassi, R. A. ^{[1
]}

Donzelli, C. ^{[2
]}

Falchetti, M. ^{[2
]}

Fontana, P. ^{[3
]}

Grigolato, P. G. ^{[2
]}

Pecorelli, S. ^{[1
]}

机构：

[1] Univ Brescia, Dept Obstet & Gynecol, Div Gynecol Oncol, Brescia, Italy

[2] Univ Brescia, Dept Pathol, Brescia, Italy

[3] Hosp Desenzano Garda, Dept Pathol, Brescia, Italy

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2008年 / 18卷 / 01期

关键词：

Her-2/neu; real-time PCR; uterine serous papillary carcinoma;

D O I：

10.1111/j.1525-1438.2007.00946.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Uterine serous papillary carcinoma (USPC) is a rare and highly malignant form of endometrial cancer (EC) characterized by early metastasis, chemoresistance, and high mortality rate. Little is known about USPC tumorigenesis even if recently a HER-2/neu role has been suggested in its development and progression. The aim of the present study was to evaluate HER-2 expression by immunohistochemistry (IHC) in 12 USPC formalin-fixed, paraffin-embedded (FFPE) samples. Moreover, we looked at the correlation between HER-2 protein expression and HER-2/neu gene amplification by fluorescence in situ hybridization (FISH), other than HER-2/neu messenger RNA expression by quantitative real-time reverse transcription (RT)-polymerase chain reaction (PCR). Finally, these results have been compared with commonly evaluated clinical features in EC patients, in order to define the potential prognostic value of HER-2/neu overexpression in USPCs. A high expression of HER-2 protein by IHC was noted in 2 of 12 patients (16.6%), and the same cases showed specific HER-2/neu gene amplification by FISH. All the samples investigated displayed a perfect concordance between IHC and FISH data. Five (41.6%) of 12 tumors demonstrated polysomy of chromosome 17 and, focusing on the 2 USPCs that showed HER-2/neu overexpression, one of them (50%) was polysomic for chromosome 17. All the other USPC cases (58.4%) showed to be disomic for chromosome 17. Quantitative RT real-time PCR performed on complementary DNA obtained from all FFPE USPC samples showed a complete correlation with FISH and IHC data. Moreover, HER-2/neu overexpression was associated with a poorer overall survival and a very low relapse-free survival time, thus being considered a candidate marker of worse overall prognosis in USPC. The use of trastuzumab (Herceptin), a monoclonal antibody directed against HER-2/neu, for the therapy of patients with HER-2/neu-positive USPCs should be further investigated in clinical trials.

引用

页码：14 / 21

页数：8

共 47 条

[1] Towards quantitative mRNA analysis in paraffin-embedded tissues using real-time reverse transcriptase-polymerase chain reaction - A methodological study on lymph nodes from melanoma patients [J].

Abrahamsen, HN ;

Steiniche, T ;

Nexo, E ;

Hamilton-Dutoit, SJ ;

Sorensen, BS .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2003, 5 (01) :34-41

[2] Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy [J].

Bellone, S ;

Palmieri, M ;

Gokden, M ;

Joshua, J ;

Roman, JJ ;

Pecorelli, S ;

Cannon, MJ ;

Santin, AD .

GYNECOLOGIC ONCOLOGY, 2003, 91 (01) :231-240

[3] OVEREXPRESSION OF HER-2 NEU IN ENDOMETRIAL CANCER IS ASSOCIATED WITH ADVANCED STAGE DISEASE [J].

BERCHUCK, A ;

RODRIGUEZ, G ;

KINNEY, RB ;

SOPER, JT ;

DODGE, RK ;

CLARKEPEARSON, DL ;

BAST, RC .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (01) :15-21

[4]

BERCHUCK A, 1990, CANCER RES, V50, P4087

[5] HER-2/neu (erbB-2) and the cell cycle [J].

Busse, D ;

Doughty, RS ;

Arteaga, CL .

SEMINARS IN ONCOLOGY, 2000, 27 (06) :3-8

[6] UTERINE PAPILLARY SEROUS CARCINOMA - A STUDY ON 108 CASES WITH EMPHASIS ON THE PROGNOSTIC-SIGNIFICANCE OF ASSOCIATED ENDOMETRIOID CARCINOMA, ABSENCE OF INVASION, AND CONCOMITANT OVARIAN-CARCINOMA [J].

CARCANGIU, ML ;

CHAMBERS, JT .

GYNECOLOGIC ONCOLOGY, 1992, 47 (03) :298-305

[7]

Cianciulli AM, 2003, J EXP CLIN CANC RES, V22, P265

[8] P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression [J].

Coronado, PJ ;

Vidart, JA ;

Lopez-asenjo, JA ;

Fasero, M ;

Furio-bacete, V ;

Magrina, J ;

Escudero, M .

EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2001, 98 (01) :103-108

[9]

CREASMAN WT, 2003, INT J GYNECOL OBS S1, V83, P119

[10] Optimal management for surgically Stage 1 serous cancer of the uterus [J].

Elit, L ;

Kwon, J ;

Bentley, J ;

Trim, K ;

Ackerman, I ;

Carey, M .

GYNECOLOGIC ONCOLOGY, 2004, 92 (01) :240-246

← 1 2 3 4 5 →